Lilly secures FDA approval for wider use of Forteo

07/24/2009 | Forbes

The FDA authorized Eli Lilly and Co. to promote its osteoporosis drug Forteo for treating patients who take glucocorticoid medications for rheumatoid arthritis, obstructive pulmonary disease and other inflammatory conditions. Forteo was approved in 2002 to treat osteoporosis in adults.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA